Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission
Stopped Never opened to accrual, a GOG working number, not developed into a clinical trial.
Conditions
- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
Interventions
- BIOLOGICAL: immunological adjuvant OPT-821
- BIOLOGICAL: polyvalent antigen-KLH conjugate vaccine
Sponsor
Gynecologic Oncology Group
Collaborators